Related Experiment Videos
The diagnostic usefulness of measuring antineutrophil antibodies in neutropenic patients
Abstract:
We prospectively evaluated the usefulness of measuring antineutrophil (PMN) antibodies in patients with neutropenia by a sensitive immunoassay. The result of the immunoassay were compared to a standard leukoagglutination test. Thirty-two patients with neutropenia were studied. The mean value (+/- 1 SD) for PMN-bound IgG for 43 normal controls was 121 +/- 29 fg/PHN. All fifteen patients with immune neutropenia had elevated plasma levels of anti-PMN antibody (191-2,000 fg/PMN). The leukoagglutination assay was positive in 10 of these 15 patients. In 17 patients with nonimmune neutropenia, the mean value (+/- 1 SD) for PMN-bound IgG was 120 +/- 22 fg. Seventeen patients with sero-positive rheumatoid arthritis but normal PMN counts were also studied. These patients' plasmas bound 447 +/- (1 SD) 201 fg IgG/PMN. The leukoagglutination test was negative in these patients. Our study shows that the immunoassay is more sensitive than leukoagglutination testing for diagnosing immune neutropenia. Nonimmune, neutropenic patients' plasmas showed no increased reactivity. In nonneutropenic patients who have high titers of rheumatoid factor, immunoreactivity against PMN is measured by the immunoassay, but not by leukoagglutination testing. Binding assays may be more sensitive than leukoagglutination testing for measuring anti-PMN antibodies; however, in some cases, specificity of such testing may be increased with leukoagglutination testing.
Insights
A sensitive immunoassay for detecting antineutrophil (PMN) antibodies is more effective than standard leukoagglutination tests for diagnosing immune neutropenia. This method shows increased sensitivity in identifying anti-PMN antibodies.
Area of Science:
- Immunology
- Hematology
Background:
- Neutropenia, a condition characterized by low neutrophil counts, can be immune-mediated or non-immune.
- Accurate diagnosis of immune neutropenia is crucial for appropriate patient management.
- Existing diagnostic methods, such as leukoagglutination, may have limitations in sensitivity.
Purpose of the Study:
- To evaluate the diagnostic utility of a sensitive immunoassay for detecting antineutrophil (PMN) antibodies in patients with neutropenia.
- To compare the performance of this immunoassay with the standard leukoagglutination test.
- To assess the specificity of the immunoassay in differentiating immune from non-immune neutropenia and in patients with rheumatoid factor.
Main Methods:
- Prospective evaluation of 32 patients with neutropenia.
- Measurement of PMN-bound IgG using a sensitive immunoassay.
- Comparison of immunoassay results with a standard leukoagglutination test.
- Inclusion of normal controls, patients with immune neutropenia, non-immune neutropenia, and rheumatoid arthritis patients with normal neutrophil counts.
Main Results:
- The immunoassay detected elevated anti-PMN antibodies in all 15 patients with immune neutropenia, whereas the leukoagglutination test was positive in only 10.
- Patients with non-immune neutropenia showed no increased reactivity with the immunoassay.
- In nonneutropenic rheumatoid arthritis patients with high rheumatoid factor titers, the immunoassay detected anti-PMN antibodies, but the leukoagglutination test did not.
Conclusions:
- The sensitive immunoassay is more effective than leukoagglutination testing for diagnosing immune neutropenia.
- The immunoassay demonstrates high sensitivity for detecting anti-PMN antibodies.
- While the immunoassay offers increased sensitivity, leukoagglutination testing may provide enhanced specificity in certain clinical scenarios.